This site is intended for Healthcare Professionals only

Clinical education & evidence platform for UK primary care clinicians.

Clinical evidence moves faster than guidelines. Our medical team filters, curates, reports and educates on what has changed and how it impacts primary care practice. Providing you a trusted central reference point you can come back to, so you're always current.

Evidence-based content
NICE Guidelines aligned
Written for UK primary care

Type 2 Diabetes

View all

Cardiovascular Disease

View all

Chronic Kidney Disease

View all

Women's Health

View all

AI & Digital Health

View all

Obesity

View all

GLP-1 & Obesity:
what every GP needs to know.

From semaglutide to tirzepatide: the evidence on weight management medications is moving fast. Our clinical team breaks down what the latest trials mean for prescribing in primary care.

Read the GLP-1 coverage

Prescribing Safety

View all

Mental Health

View all

Primary Care Policy

View all

Neurology

View all

Public Health

View all

Respiratory

View all

Built for the pace of modern primary care.

Primary care focus

Medicine Central is curated especially for UK primary care, with contributions from guest expert clinicians.

Evidence-based

Peer-reviewed sources only, with study design and limitations reported alongside the headline.

CPD-ready

CPD-eligible webinars let you log time against your appraisal portfolio.

Key publications in 50 words

MicroMedicine Central

View all
British Journal of General Practice· 12 November 2026

The non-cancer diagnoses recorded in the year before a cancer

Researchers from Exeter, Oxford and Queen Mary London used English GP records to compare 111,711 people diagnosed with cancer with matched controls. One in five had a non-cancer diagnosis coded in the year before. Thirty-seven of these were linked to outcomes, 18 consistently worse. UTI before bladder cancer and constipation before colorectal or ovarian cancer predicted later stage and emergency presentation. Pneumonia before lung cancer was worse on every outcome. The authors' answer is safety-netting while the diagnosis is still uncertain.

Inflammatory Bowel Diseases· 12 November 2026

Faecal calprotectin testing rose from 1.6% to 7.7%, and a quarter with a normal result were still referred

Among 830,936 adults aged 18 to 60 with lower GI symptoms in English primary care, testing rose from 1.6% in 2015 to 7.7% in 2023. A quarter of those with a result below 100 µg/g were referred anyway. Among those referred despite a normal result, 0.5% were diagnosed with IBD and 1% with colorectal cancer. The test does its job for IBD. It is not a cancer test, and red-flag symptoms still need a referral whatever the result.

Diabetes, Obesity and Metabolism· 12 November 2026

Most patients stop semaglutide within a year. A stalled first dose is the early warning

Clalit Health Services in Israel followed 34,309 adults without diabetes starting semaglutide for obesity. The estimated probability of discontinuation by one year was 67.6%, based on dispensing gaps. Patients still on the 0.25 mg starting dose at day 90 had a higher subsequent discontinuation hazard than those on 1.0 mg (HR 1.88). This association was largely explained by early refill adherence, not proof of why patients stopped. If the dose has not moved by three months, that is the moment to ask why. Patients paid half the cost, so UK persistence may differ.

Diabetes, Obesity and Metabolism· 15 October 2026

SGLT2 inhibitors: cardiorenal benefit across 14 trials

Across 14 placebo-controlled trials in 76,969 adults with type 2 diabetes, SGLT2 inhibitors reduced first heart-failure admission or cardiovascular death by 23% (HR 0.77) and composite kidney events by 31% (HR 0.69). Kidney outcome definitions differed across trials, so the kidney estimate needs cautious interpretation.

Nephrology Dialysis Transplantation· 15 October 2026

Cystatin C reclassified 15% to a more advanced CKD stage

In over 400,000 UK Biobank participants, replacing creatinine with cystatin C reclassified 15% to a more advanced CKD stage. People with four or more long-term conditions had over four-fold higher odds of a large negative eGFR difference. This observational study does not show that cystatin C testing improves outcomes.

This week's edition

This week's key publications, each summarised in 50 words by our clinical team.

Read MicroMedicine

Built for clinicians

  • ✓Unlimited access to clinical evidence articles
  • ✓Weekly newsletter with clinical evidence
  • ✓Free for registered healthcare professionals
GPsPharmacistsNursesDietitiansParamedicsPhysiotherapists
Join free

We will never share your contact information.

Medical Disclaimer: The content on Medicine Central is intended solely for registered healthcare professionals and is provided for educational and informational purposes only. It does not constitute medical advice, clinical guidance, or a substitute for professional clinical judgment. Always refer to current NICE guidelines, local formularies, and your own clinical assessment when making patient care decisions. Medicine Central accepts no liability for any loss, harm, or damage arising from reliance on the information provided. Content is reviewed periodically but may not reflect the most recent evidence or guideline updates. This site is not intended for use by patients or the general public.

Medicine CentralMedicine Central

Clinical education and evidence for healthcare professionals. Free for registered healthcare professionals.

Newsletter

The weekly Medicine Central newsletter: curated clinical evidence for healthcare professionals. Free, and you can unsubscribe at any time.

Join free

© 2026 Medicine Central. All rights reserved.